Welcome to AZ MedX

AstraZeneca’s Respiratory & Immunology medical resource centre for healthcare professionals

Discover the latest advances and approaches in asthma, COPD and more

This site is intended for the use of Healthcare Professionals only. By clicking the link below you declare and confirm:

If you are not a Healthcare Professional, please follow this link for information on global patient resources.

What is the NOVELTY study?

NOVELTY (NOVEL observational longiTudinal studY) is a global, prospective, 3-year study of patients with a physician-assigned diagnosis of asthma and/or chronic obstructive pulmonary disease (COPD), with an additional extension study visit at participating sites.

NOVELTY aims to describe patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, to re-frame obstructive lung disease by enabling the move towards a preventive- and precision medicine-led clinical paradigm. The NOVELTY study is sponsored by AstraZeneca.

The NOVELTY website


Watch our short animation to learn more about the NOVELTY study

  • Respiratory Symptoms Questionnaire

    An article examining the reliability and validity of the novel Respiratory Symptoms Questionnaire (RSQ) in patients with asthma and/or COPD in the NOVELTY study has been published in ERJ Open Research.

    downloadDownload a PDF of the RSQ validation infographic

You are now leaving: http://azmedx.com/

By following this link you will be leaving the AZ MedX website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to AZ MedX